Kappa Opioid Receptors, A New Treatment Target for Schizophrenia, Dr Samuel Clark - Terran Biosciences Inc and Stony Brook University

Schizophrenia is a serious psychiatric disorder that affects around 1% of the global population, producing debilitating symptoms that significantly impact upon the quality of life of sufferers. Even with treatment, prognosis is often poor with a high risk of relapse. Dr Samuel Clark of Terran Biosciences Inc and colleagues at Stony Brook University, New York, are investigating the potential of blocking one type of opioid receptor in the brain – the kappa receptor – to reduce the symptoms of the disease.